NPHC (Nutra Pharma) Cyclically Adjusted PB Ratio: (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Nutra Pharma Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation

Nutra Pharma  (OTCPK:NPHC) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.

Nutra Pharma Cyclically Adjusted PB Ratio Related Terms

Nutra Pharma Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Nutra Pharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nutra Pharma Cyclically Adjusted PB Ratio Chart

Nutra Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nutra Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NPHC vs UPC, CBIH, SXTC: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nutra Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nutra Pharma Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nutra Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nutra Pharma's Cyclically Adjusted PB Ratio falls into.


Nutra Pharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Nutra Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Nutra Pharma's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.002/330.2130*330.2130
=-0.002

Current CPI (Mar. 2026) = 330.2130.

Nutra Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201606 -0.028 241.018 -0.038
201609 -0.018 241.428 -0.025
201612 -0.015 241.432 -0.021
201703 -0.014 243.801 -0.019
201706 -0.006 244.955 -0.008
201709 -0.003 246.819 -0.004
201712 -0.003 246.524 -0.004
201803 -0.002 249.554 -0.003
201806 -0.002 251.989 -0.003
201809 -0.001 252.439 -0.001
201812 -0.001 251.233 -0.001
201903 -0.002 254.202 -0.003
201906 -0.002 256.143 -0.003
201909 -0.002 256.759 -0.003
201912 -0.002 256.974 -0.003
202003 -0.001 258.115 -0.001
202006 -0.002 257.797 -0.003
202009 -0.001 260.280 -0.001
202012 -0.002 260.474 -0.003
202103 -0.006 264.877 -0.007
202106 -0.005 271.696 -0.006
202109 -0.003 274.310 -0.004
202112 -0.003 278.802 -0.004
202203 -0.002 287.504 -0.002
202206 -0.002 296.311 -0.002
202209 -0.002 296.808 -0.002
202212 -0.002 296.797 -0.002
202303 -0.002 301.836 -0.002
202306 -0.002 305.109 -0.002
202309 -0.002 307.789 -0.002
202312 -0.002 306.746 -0.002
202403 -0.002 312.332 -0.002
202406 -0.002 314.175 -0.002
202409 -0.002 315.301 -0.002
202412 -0.002 315.605 -0.002
202503 -0.002 319.799 -0.002
202506 -0.002 322.561 -0.002
202509 -0.002 324.800 -0.002
202512 -0.002 324.054 -0.002
202603 -0.002 330.213 -0.002

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Nutra Pharma Business Description

Address 6400 Park of Commerce Boulevard, Suite 1B, Boca Raton, FL, USA, 33487
Nutra Pharma Corp operates as a biopharmaceutical company with intellectual property for drugs that treat autoimmune disorders, viral diseases, and pain. It is focused on homeopathic and drug discovery research and clinical development, and has developed four homeopathic drugs for the relief of pain: Nyloxin and Nyloxin Extra Strength, Pet Pain-Away, Equine Pain-Away, and Luxury Feet. Additionally, the company has developed two drug candidates: RPI-78M, to treat neurological diseases and autoimmune diseases; and RPI-MN, to treat viral diseases, including HIV/AIDS and Herpes. Nutra Pharma produces, markets, and distributes its branded products both domestically and internationally.